BioPorto
1,628 DKK +11,35%HC Andersen Capital saa maksun yhtiöltä BioPorto DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Lue lisääViimeisimmät analyysit
Analyst
Viimeisimmät videot
Pörssikalenteri
First Quarter 2024: Strong growth in US sales of The NGAL Test
Resolutions of Annual Geneal Meeting
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.